Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2011

View Archived Issues

COR-II and substudy evaluate weight loss and blood pressure during Contrave treatment of obesity

Amira Pharma claims new arachidonate 5-lipoxygenase inhibitors

Astellas launches new tablet formulation of Vesicare for overactive bladder

Novel PARP-1 inhibitor HYDAMTIQ is efficacious in models of brain ischemia

FDA approves Rituxan for Wegener's granulomatosis and microscopic polyangiitis

BioSante Pharma licenses cancer vaccines to Aduro BioTech

PET tracer BAY-86-4367 is safe in subjects with primary prostate cancer in phase I study

Expression of transient receptor potential TRPM7 channel predicts poor survival in NPC

Baxter enters definitive agreement to acquire Prism Pharmaceuticals

Presidio Pharma updates progress of HCV NS5A inhibitors PPI-461, PPI-437, PPI-668 and PPI-833

CH-5424802 shows promise in ALK-positive tumors and advances in phase I/II trial in NSCLC

Clopidogrel reduces obliterative airways disease after trachea transplantation in mice

University of Illinois patents new integrin alpha-IIb/beta-3 antagonists

University of California presents new bladder cancer-specific ligand peptides

SciClone acquires NovaMed Pharmaceuticals

Marina Biotech completes enrollment of first cohort in START-FAP trial of CEQ-508

Osta Biotechnologies announces promising preclinical results for OB-28 in Alzheimer's disease

Biothera's second phase II trial of Imprime PGG in NSCLC achieves stage-1 endpoint

New inhibitors of hepatocyte growth factor receptor designed

Genmab and Seattle Genetics form second antibody-drug conjugate collaboration

New modulators of nuclear receptor related 1 receptor claimed

DiaMedica reports preclinical data on DM-204 in type 2 diabetes

Oncolytics Biotech reports interim data from Reolysin trial in metastatic colorectal cancer

Novel 11-beta-HSD1 inhibitors reported by University of Edinburgh

Dynavax commences first phase I trial of DV-1179 in lupus

Enrollment open in phase IIb trial of intravenous omecamtiv mecarbil in acute heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...